Cytochrome c

Cytochrome c: A Comprehensive Reference

1. Identity, Chemical Description, and Natural Sources

1.1 Names and Chemical Identity

Cytochrome c is a highly conserved small soluble heme-containing protein with a molecular weight of approximately 12 kDa. Its systematic biochemical designation is ferrocytochrome c / ferricytochrome c (depending on its oxidation state), and it belongs to the c-type cytochrome family. It is a small globular protein containing an iron porphyrin cofactor (heme c) that is covalently bound to a single polypeptide chain. The iron atom at the centre of the heme group undergoes reversible redox cycling between ferrous (Fe²⁺) and ferric (Fe³⁺) oxidation states as it performs its functional roles.

Consisting of 104 amino acids in humans, horses, and mice, cytochrome c is a redox-active molecule that is encoded in the nucleus and synthesized as apocytochrome c. It is transported across the outer mitochondrial membrane into the intermembrane space, where it is converted into holocytochrome c by holocytochrome-c synthase to become the mature protein with the heme group covalently linked to Cys-14 and Cys-17.

Two hundred and eighty-five complete amino acid sequences of cytochrome c from different species are known. Sequence analysis suggests that the number of amino acid residues in most mitochondrial cytochromes c is in the range 104 ± 10, and amino acid residues at only a few positions are highly conserved throughout evolution. These highly conserved residues include Cys14, Cys17, His18, Gly29, Pro30, Gly41, Asn52, Trp59, Tyr67, Leu68, Pro71, Pro76, Thr78, Met80, and Phe82, also known as "key residues," which contribute significantly to the structure, function, folding, and stability of cytochrome c.

1.2 Natural Sources

Cytochrome c is found in all aerobic eukaryotes—animals, plants, yeasts, and fungi—where it resides in the mitochondrial intermembrane space. In animals, organs rich in mitochondria with high metabolic rate, such as the heart and brain, are primary sources, though other mitochondria-rich organs such as the liver, kidney, pancreas, and skeletal muscle also contain substantial amounts.

For laboratory and industrial extraction, cytochrome c is extracted from ground and homogenized tissue with a dilute solution of aluminum sulfate at pH 4.5; at slightly alkaline pH, excess aluminum ions are precipitated as the hydroxide and exchanged for three monovalent ammonium ions. The cytochrome c is then purified by ammonium sulfate fractionation, cation exchange chromatography, and crystallization. This method of extraction is suited to vertebrate and invertebrate tissues, but for plant materials, protists, or fungi, special cytolysis procedures are often required.

Researchers have isolated cytochrome c from cow heart and liver tissue without manipulating cell signaling pathways. Commonly used isolation methods have historically not taken into account the possibility of cytochrome c phosphorylation in vivo, resulting in the isolation of dephosphorylated protein, including those available from commercial sources, and therefore its potential as an integral target of cellular signaling was overlooked.

Cytochrome c is a basic protein with a molecular weight near 12,300. Its intense red color in solution, owing to the heme c cofactor's characteristic absorption bands in the visible spectrum, was a property that enabled its historical discovery.

1.3 Common Forms and Preparations

Cytochrome c is available in several forms for research and potential therapeutic use:

• Native protein isolated from tissue: Purified from animal sources (commonly bovine heart or horse heart) via the procedures described above. Commercial preparations are widely available for research purposes.
• Recombinant protein: Produced via microbial or cell-based expression systems, allowing generation of human-sequence cytochrome c with defined post-translational modification states.
• Nanoparticle-encapsulated forms: Composite nanoparticles bearing cytochrome c can act as a proapoptotic mediator; the introduction of exogenous cytochrome c via absorption of carrier particles, the phagocytosis of colloid particles of submicrometric size, or the receptor-mediated endocytosis of nanoparticles in cancer cells initiates the process of apoptosis.
• Chemically modified protein conjugates: A carrier-free method involves chemically modifying cytochrome c with an acid-responsive cell-penetrating peptide (CPP) for selective intracellular delivery within tumours; in the acidic tumour microenvironment, the modification deprotects and exposes a positively charged CPP, enabling membrane penetration.

No standardized oral dietary supplement form of cytochrome c has been approved by major regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the European Food Safety Authority (EFSA) as of the available literature. Its investigation as a supplement or therapeutic agent has been confined largely to injectable or nanoparticle-based delivery research settings.

2. Historical Discovery and Scientific Lineage

Cytochrome c does not carry a history of traditional ethnomedical use in the sense of herbalism or folk medicine. Its history is entirely scientific, rooted in nineteenth- and twentieth-century biochemistry.

In 1884, Charles Alexander MacMunn reported the discovery of a novel pigment in muscle tissue, which he termed "myohaematin," based on its distinct absorption spectrum observed through spectroscopic analysis of various animal tissues, including invertebrates and vertebrates. He expanded on this in 1886, describing a broader class of similar pigments called "histohaematins," found in a range of tissues beyond muscle, such as blood, urine, and organs, and proposed they functioned as respiratory pigments distinct from hemoglobin. These findings were largely overlooked by the scientific community at the time, possibly due to skepticism about the reliability of tissue spectroscopy.

Cytochrome c was rediscovered by David Keilin in 1925, and the crystal structure was reported by Dickerson and colleagues in 1971; since that time cytochrome c remains among the most intensively studied proteins because of its vital function in living organisms. In 1925, building on initial observations by Charles MacMunn decades earlier, David Keilin identified such respiratory pigments and dubbed them "cytochromes," paving the way for Keilin, Warburg, Hartree, and others to flesh out the concept of a "respiratory chain."

In 1931, in part for describing the nature of the cytochromes, Warburg won the Nobel Prize "for his discovery of the nature and mode of action of the respiratory enzyme." Subsequent decades produced a detailed structural and functional picture: in 1946, Albert Claude worked out the first differential centrifugation techniques to isolate mitochondria and demonstrated that succinoxidase and cytochrome oxidase are mitochondrial.

The role of cytochrome c in apoptosis was established much later. The landmark finding that cytochrome c release from mitochondria triggers the caspase cascade came from the laboratory of Xiaodong Wang at the University of Texas Southwestern Medical Center in the late 1990s, transforming the understanding of programmed cell death and opening a new chapter in oncology and cell biology research.

3. Key Constituents and Active Compounds

3.1 Protein Architecture

Cytochrome c is a small globular protein containing an iron porphyrin cofactor (heme c) that is covalently bound to the only polypeptide chain. The heme c structure positions the porphyrin ring perpendicular to the protein backbone, optimizing solvent exposure of the heme edges for rapid electron exchange with partner proteins.

Reduction and oxidation of an iron molecule (Fe³⁺ to Fe²⁺ and back) within its central heme group allow it to receive an electron from the cytochrome c1 subunit of cytochrome reductase and pass it to cytochrome a within the cytochrome oxidase complex.

3.2 Post-Translational Modifications

Cytochrome c was shown to be a target of cellular signaling pathways that regulate its functions by tissue-specific phosphorylations; so far five phosphorylation sites have been mapped and functionally characterized — Tyr97, Tyr48, Thr28, Ser47, and Thr58 — and all five phosphorylations partially inhibit respiration, resulting in optimal intermediate mitochondrial membrane potentials and low reactive oxygen species (ROS) production under normal conditions.

Four of the phosphorylations result in inhibition of the apoptotic functions of cytochrome c, suggesting a cytoprotective role for phosphorylated cytochrome c; interestingly, these phosphorylations are lost during stress conditions such as ischemia, resulting in maximal ETC flux during reperfusion, mitochondrial membrane potential hyperpolarization, excessive ROS generation, and apoptosis.

The well-documented post-translational modifications of cytochrome c could further contribute to the rapid adjustment of electron flow in response to changing cellular conditions.

4. Established Mechanisms of Action

4.1 Electron Carrier in the Respiratory Chain

The main function of cytochrome c is its involvement in the electron transport chain of the mitochondrial inner membrane; it is a key element that ensures cellular respiration. As an electron is transferred from ubiquinol–cytochrome c reductase (Complex III) to cytochrome c oxidase (Complex IV) in the mitochondrial respiratory chain, cytochrome c is reversibly reduced and oxidized.

Complexes I (NADH dehydrogenase) and II (succinate dehydrogenase) use electrons to reduce coenzyme Q, which transfers these electrons to Complex III (cytochrome bc1 complex); cytochrome c receives electrons from Complex III and shuttles them to Complex IV (cytochrome c oxidase), which in turn uses them to reduce molecular oxygen to water.

The soluble electron carrier cytochrome c has recently emerged as an essential factor in the assembly and function of respiratory supercomplexes. A "restricted diffusion pathway" mechanism for electron transfer between Complexes III and IV has been proposed based on secondary, distal binding sites for cytochrome c at its two membrane partners recently discovered.

A model proposes that the electron transfer from cytochrome c to cytochrome c oxidase is the rate-limiting step of the ETC, which is regulated via post-translational modifications of cytochrome c.

4.2 Apoptosis Initiation (Intrinsic Pathway)

Cytochrome c is an electron carrier in the mitochondrial electron transport chain and thus central for aerobic energy production; under conditions of cellular stress, cytochrome c release from mitochondria is a committing step for apoptosis, leading to apoptosome formation, caspase activation, and cell death.

Upon apoptotic stimuli, cytochrome c is released from mitochondria into the cytoplasm where it oligomerizes with Apaf-1 forming a complex known as the apoptosome; each apoptosome then recruits caspase 9, which leads to activation by self-proteolysis.

Translocation of cytochrome c from mitochondria to the cytoplasm is a key step in the initiation and/or amplification of apoptosis. Calcium-induced cytochrome c release, as occurs in neurons during stroke and ischemia, involves rupture of the mitochondrial outer membrane and can be blocked by inhibitors of the mitochondrial permeability transition.

4.3 Antioxidant Activity

In addition to its well-known roles in the electron transport chain and cell apoptosis, according to a 2008 study cytochrome c can also act as an antioxidative enzyme in the mitochondria; it does so by removing superoxide (O⁻₂) and hydrogen peroxide (H₂O₂) from mitochondria. Cytochrome c can also catalyze several redox reactions such as hydroxylation and aromatic oxidation, and shows peroxidase activity by oxidation of various electron donors.

Presence of peroxynitrite or H₂O₂ and nitrogen dioxide in the mitochondria can be lethal since they nitrate tyrosine residues of cytochrome c, which leads to disruption of cytochrome c's function as an electron carrier in the electron transport chain.

4.4 Cardiolipin Peroxidase Activity

Recent discoveries of additional functions of cytochrome c include its activity as a cardiolipin peroxidase, and the detection of four phosphorylation sites, suggesting that its multiple functions are regulated by cell signaling pathways. Recent research highlights its role as a cardiolipin peroxidase, which catalyzes cardiolipin peroxidation — a process that encourages cytochrome c release from mitochondria, fostering apoptosis.

4.5 Regulation of Supercomplex Assembly

The soluble electron carrier cytochrome c has recently emerged as an essential factor in the assembly and function of respiratory supercomplexes; a "restricted diffusion pathway" mechanism for electron transfer between Complexes III and IV has been proposed based on the secondary, distal binding sites for cytochrome c, and this channeling pathway facilitates the surfing of cytochrome c on both respiratory complexes, thereby tuning the efficiency of oxidative phosphorylation.

5. Body Systems and Health Areas Associated with Cytochrome c

5.1 Cellular Energy Metabolism

The primary role of cytochrome c lies in participating within the Electron Transport Chain situated on the inner membrane of mitochondria, thereby serving as a pivotal component crucial for cellular respiration maintenance. Because virtually all aerobic ATP synthesis depends on the intact function of the ETC, cytochrome c is indirectly relevant to every organ system that relies on oxidative phosphorylation, including the brain, heart, liver, skeletal muscle, and kidney.

5.2 Cardiovascular System

Cytochrome c regulation in respiration and cell death is discussed in a human disease context including neurodegenerative and cardiovascular diseases, cancer, and sepsis. Dysregulation of cytochrome c release is implicated in ischemia-reperfusion injury. The augmentation of intracellular calcium signaling leads to the formation of the mitochondrial permeability transition pore (mPTP), and as a result, cytochrome c is released into the cytoplasm to activate caspase family proteins.

5.3 Nervous System

Apoptosis is critical for normal development and tissue homeostasis; however, its abnormal occurrence has been implicated in a number of disorders, including neurodegenerative diseases and stroke. Familial ALS, a chronic neurodegenerative disease, is characterized by the presence of high levels of ROS due to mutations in the radical scavenger superoxide dismutase; increased ROS levels damage cells, eventually resulting in loss of specific motor neuron populations through apoptosis.

5.4 Oncology

Reduced levels of cytochrome c have been observed in cancer tissues, indicating a potential inhibition of apoptosis; for instance, in glioma tissues, cytochrome c levels were lower compared to healthy tissues, and this reduction became more pronounced in advanced stages of the disease. Cytochrome c emerges as a significant target for the signaling of cancer cells, due to its dual roles in oxidative phosphorylation and the intrinsic apoptosis pathway.

5.5 Liver

A study of drug-induced hepatotoxicity revealed that cytochrome c can be used as a marker of liver injury. Serum levels of cytochrome c were found to be increased in patients with several liver diseases; mean serum cytochrome c concentration was 187.1 ng/mL in patients and only 39.8 ng/mL in healthy controls, and in these patients cytochrome c level was correlated well with other biochemical markers of liver injury as well as with the necroinflammatory score and the apoptotic index of liver biopsies.

5.6 Immune and Inflammatory Systems

Cytochrome c can be released into the extracellular space by damaged or dying cells, potentially serving as a signaling molecule that alerts nearby cells to tissue damage; elevated levels of serum cytochrome c have been observed in various conditions, such as inflammatory arthritis, myocardial infarction, and liver diseases, and it may also indicate mitochondrial injury following events like heart failure resuscitation, snakebite envenomation, and chemotherapy.

Cytochrome c released into the bloodstream can trigger immune responses in astrocytes through interaction with toll-like receptor 4 (TLR4), suggesting that targeting the cytochrome c–TLR4 pathway might help reduce inflammation resulting from cell death.

6. Scientific Evidence by Area of Use

6.1 Cytochrome c as a Biomarker in Critical Illness and Sepsis

The most substantive and clinically validated use of cytochrome c is as a circulating biomarker of apoptosis and organ injury, not as a supplement administered to patients. Measurement of serum or plasma cytochrome c offers a window into the degree of mitochondrial damage occurring in critical illness.

Systemic Inflammatory Response Syndrome (SIRS) and Multiple Organ Dysfunction Syndrome (MODS): Apoptosis may play an important role in the development of SIRS and progression to MODS; in a study developing a sandwich ELISA system, cytochrome c concentrations in 53 SIRS patients with or at risk for MODS ranged from 0.24–210 ng/mL, whereas those in 14 control subjects were under detection limits (0.1 ng/mL); cytochrome c concentrations in non-survivors increased significantly compared with survivors both on the day of admission and on the fifth hospital day. The authors concluded that determination of serum cytochrome c concentrations may be useful to assess the severity of organ dysfunction and to predict the prognosis of SIRS/MODS patients.

Cardiac Arrest and Resuscitation: Calcium overload and reactive oxygen species can injure mitochondria during ischemia and reperfusion; a study measured plasma cytochrome c using reverse-phase high performance liquid chromatography and western immunoblotting in rats undergoing 4 or 8 minutes of untreated ventricular fibrillation and 8 minutes of closed-chest resuscitation followed by 240 minutes post-resuscitation observation. Plasma cytochrome c rose progressively, attaining levels 10-fold higher than in sham rats at 240 minutes post-resuscitation, and cytochrome c levels inversely correlated with left ventricular stroke work. Evidence strength: preclinical (animal model); direct clinical translation remains investigational.

Sepsis-Induced Myocardial Injury: A study in rats using a lipopolysaccharide-induced sepsis model investigated cytochrome c release in the heart by immunohistochemistry. Septic animals showed decreased contractility and lower developed pressure; however, immunohistochemistry revealed no release of cytochrome c in healthy or septic hearts, concluding that cytochrome c is not released during sepsis-induced myocardial depression. This conflicts with other findings and underscores that cytochrome c release is context-dependent.

Septic Mice — Exogenous Administration: Intravenous administration of cytochrome c in septic mice has been shown to restore cytochrome c oxidase activity in damaged myocardium, leading to a significant improvement in survival. Evidence strength: animal study only; no controlled human trials of IV cytochrome c administration in sepsis are established in the available literature.

6.2 Cytochrome c in Cancer: Biomarker Evidence

Several clinical studies have confirmed release of cytochrome c into the extracellular space and, finally, into the circulation in various conditions characterized by cell death, including patients with myocardial infarction.

Non-Small Cell Lung Cancer (NSCLC): A clinical study measured cytochrome c levels in serum of 100 non-small cell lung cancer patients and 100 healthy controls using enzyme-linked immunosorbent assay. About a threefold lower serum cytochrome c level was observed in newly diagnosed NSCLC patients than in healthy individuals; patients in advanced stages and with grade 3 histological differentiation showed significantly low levels of serum cytochrome c, and lower levels were associated with worse survival outcome. Serum cytochrome c level was observed to be more than 13-fold higher after the first cycle of conventional chemotherapy; patients with higher cytochrome c levels before therapy showed better response to chemotherapy; and monitoring serum cytochrome c might serve as a sensitive apoptotic marker reflecting chemotherapy-induced cell death burden.

Operable Malignant Tumors (Multi-Cancer Study): A study enrolled a total of 257 patients (232 malignant and 25 benign) to evaluate serum cytochrome c levels as a novel tumor marker; serum cytochrome c and lactate dehydrogenase were measured in all cases, and CEA and CA-19-9 were measured in subsets of gastric and colorectal cancer patients. The serum cytochrome c level was significantly higher in patients with malignant tumors than patients with benign tumors (20.6 vs. 15.5 ng/mL; P = 0.017).

Cancer Prognosis — General Observations: There are also several studies remarking on the possible role of serum cytochrome c as a prognostic marker in various types of cancer, with higher levels showing high-turnover and consequently more aggressive tumors; on the other hand, elevated levels of serum cytochrome c after chemotherapy may be a good prognostic factor, indicating increased chemotherapy-induced cancer cell apoptosis.

Evidence strength summary for cancer biomarker use: Multiple clinical observational studies support the use of serum cytochrome c as a correlative biomarker, but these are cross-sectional or cohort studies, not interventional trials. No clinical trial has demonstrated that measuring serum cytochrome c improves outcomes compared to standard markers, and no regulatory body has approved it for diagnostic use.

6.3 Cytochrome c as a Therapeutic Anticancer Agent (Investigational)

The heme protein cytochrome c plays pivotal roles in cellular life and death processes; in the respiratory chain of mitochondria it serves as an electron transfer protein contributing to the proliferation of healthy cells, while in the cell cytoplasm it activates intrinsic apoptosis to terminate damaged cells; insight into these mechanisms informs on the anticancer therapeutic potential of the protein, especially in its ability to subvert the current limitations of small molecule-based chemotherapy.

A range of delivery strategies have been explored preclinically:

• Nanoparticle delivery: Reviews discuss the synthesis, physicochemical properties, and cytotoxicity of composite nanoparticles bearing cytochrome c, which can act as a proapoptotic mediator; the introduction of exogenous cytochrome c via absorption of carrier particles, phagocytosis of colloid particles, or receptor-mediated endocytosis in cancer cells initiates the process of apoptosis.
• Targeted folate-PEG-PLGA nanoparticles for lung cancer: Protein nanoprecipitation is a structure- and activity-preserving technique that permits synthesis of cytochrome c nanoparticles (NPs) with high induction of caspase activation; around 80–90% of the caspase activity is retained in these NPs compared to the native protein.
• Iron oxide–gold nanoparticles for liver cancer: A combinatorial approach involved immobilizing cytochrome c onto the surface of hybrid iron oxide–gold nanoparticles while simultaneously supplementing cells with clinically used anticancer agents; evidence of uptake was reported on hepatocellular carcinoma (HepG2), epithelial hepatoma (Huh-7D), and endothelial hepatocellular carcinoma (SK-hep-1) cell lines.
• Acid-responsive cell-penetrating conjugate: A cell-penetrating peptide was protected with 2,3-dimethyl maleic anhydride and chemically conjugated onto the cytochrome c protein surface, creating an acid-responsive protein delivery system; in the acidic tumour microenvironment, the modification deprotects and exposes the positively charged CPP, enabling membrane penetration.

Evidence strength: All anticancer therapeutic research with cytochrome c as the active agent is currently at the preclinical (cell line and animal model) stage. No human clinical trials of cytochrome c as a direct anticancer therapeutic have been identified in the available peer-reviewed literature. Translation to clinical use faces substantial barriers, including protein stability, immunogenicity, and intracellular delivery across cell membranes.

6.4 Cytochrome c in Neurodegenerative Diseases

Derivation of the specific pathways that operate the regulatory mechanisms of cytochrome c and their effects may become an important avenue for therapeutic targeting of various human illnesses, including neurodegenerative diseases, congestive heart failure, and cancer.

A model proposes that the electron transfer from cytochrome c to cytochrome c oxidase is the rate-limiting step of the ETC, regulated via phosphorylation of cytochrome c; this regulation may be dysfunctional in disease conditions such as ischemia-reperfusion injury and neurodegenerative disorders through increased ROS, and also cancer, where phosphorylation and acetylation modifications of cytochrome c may provide a mechanism to avoid apoptosis and enable progression of the disease.

Radical scavengers have been proven beneficial in ALS transgenic mice models as well as over-expression of antiapoptotic Bcl-2 protein; minocycline, a second-generation tetracycline, confers neuroprotection in several models of neurodegeneration including delay of ALS progression in mice. These agents act at least in part by modulating cytochrome c release. Evidence strength: Primarily preclinical animal studies; no clinical trials targeting cytochrome c directly in neurodegeneration have been identified.

6.5 Cytochrome c in Glioma (Brain Cancer)

Apoptosis-regulating mechanisms are disturbed in malignant gliomas, as they are in other forms of malignancy; a study was conducted to evaluate the variation in the expression level of several apoptotic proteins responsible for apoptosis in low- to high-grade glioma, and this found a significant change in the expression of five apoptotic proteins including cytochrome c. Reduced levels of cytochrome c were observed in glioma tissues compared to healthy tissues, and this reduction became more pronounced in advanced stages of the disease. Evidence strength: Observational tissue proteomics study; no intervention.

6.6 Mitochondria-Targeting Approaches and Energy-Related Supplementation

It is important to distinguish cytochrome c from compounds that support cytochrome c's electron-accepting partner, cytochrome c oxidase (Complex IV). Studies with dietary supplements have evaluated indirect effects on cytochrome c and the ETC rather than supplementation with cytochrome c itself. For example, a clinical trial assessing the effect of epicatechin on aerobic training adaptation in healthy human subjects found that epicatechin supplementation (100 mg, twice a day) during 4 weeks of cycle training decreased the protein levels of ETC complex II, while those of other mitochondrial proteins such as citrate synthase and cytochrome c were not altered in skeletal muscle. This highlights that even interventions targeting the mitochondrial ETC do not reliably alter cytochrome c protein levels.

7. Dosage Forms and Reported Dosages

There is no established oral supplement dose of cytochrome c in human clinical literature. The protein's large molecular size (~12 kDa), susceptibility to gastrointestinal proteolysis, and dependence on intact intracellular localization for function make simple oral supplementation mechanistically implausible without specialized delivery systems. The following dosage-related information comes directly from experimental contexts documented in peer-reviewed sources:

• Nanoparticle-based intratumoral injection (preclinical mouse study): Nude mice bearing HT29 xenografts received intratumoral injections of 10 mg/mL cytochrome c conjugate (50 µL, 41.67 nmol); tumor sizes were measured at two-day intervals for a total duration of 23 days, and no significant decreases in body weight were observed, indicating a lack of discernible systemic toxicity in this model.
• Intravenous administration in septic mice (preclinical): Intravenous administration of cytochrome c in septic mice restored cytochrome c oxidase activity in damaged myocardium, leading to a significant improvement in survival. Specific doses were not reported in the available excerpt.
• No human clinical dosing data for supplemental or therapeutic cytochrome c administration have been identified in the available peer-reviewed literature.

For context, commercially purified cytochrome c (e.g., from bovine or equine heart) is available in research-grade vials in milligram quantities and used in cell-free caspase assay systems and biochemical experiments at nanomolar to micromolar concentrations.

8. Safety Considerations and Notable Interactions

8.1 Extracellular Cytochrome c as a Potentially Harmful Signal

When cytochrome c escapes from damaged cells into the extracellular environment, it behaves as a damage-associated molecular pattern (DAMP). DAMPs are molecules that are part of the innate immune response which are released from damaged or dying cells and locate to inappropriate compartments and sites; they trigger a noninfectious inflammatory response by binding to a pattern recognition receptor, signaling the damage to help mitigate further damage; cytochrome c could be useful as a biomarker of severe damage in the mitochondria or cell death.

Release of cytochrome c into the culture medium due to staurosporine-induced apoptosis of neuronal cells enhanced apoptosis further, and addition of exogenous cytochrome c in lymphocyte cultures induced apoptosis; this toxic effect of extracellular cytochrome c deserves further evaluation. This finding — that exogenous cytochrome c can itself induce cell death in normal immune cells — is a major safety concern for any proposed therapeutic or supplemental use.

8.2 Interaction with Peroxynitrite and Reactive Nitrogen Species

Presence of peroxynitrite or H₂O₂ and nitrogen dioxide in the mitochondria can be lethal since they nitrate tyrosine residues of cytochrome c, which leads to disruption of cytochrome c's function as an electron carrier in the electron transport chain. This represents an important consideration in oxidative stress-related disease states where cytochrome c function is inherently compromised.

8.3 Relationship with Ischemia-Reperfusion Injury

Phosphorylations of cytochrome c that are cytoprotective under normal conditions are lost during stress conditions such as ischemia, resulting in maximal ETC flux during reperfusion, mitochondrial membrane potential hyperpolarization, excessive ROS generation, and apoptosis. This regulation may be dysfunctional in disease conditions such as ischemia-reperfusion injury and neurodegenerative disorders through increased ROS, or cancer, where post-translational modifications of cytochrome c may provide a mechanism to avoid apoptosis.

8.4 Absence of Regulatory Approval for Supplement Use

No national or supranational food safety or drug regulatory authority — including the FDA, EMA, EFSA, WHO, or Health Canada — has evaluated or approved cytochrome c as a dietary supplement ingredient for human consumption in any form. It is not listed in the Commission E monographs, ESCOP monographs, WHO herbal monographs, or the United States Pharmacopeia (USP) dietary supplement compendium. Its complex biology, involving pro-apoptotic activity, immune stimulation through TLR4, and the absence of any evidence supporting oral absorption into functional intracellular compartments, means it occupies a fundamentally different category from conventional dietary supplements.

8.5 Potential Interactions with Cancer Chemotherapy

Serum cytochrome c level was observed to be more than 13-fold higher after the first cycle of conventional chemotherapy, and patients with higher cytochrome c levels before therapy showed better response to chemotherapy in terms of significantly higher serum cytochrome c after the first cycle. These observations suggest that cytochrome c levels are dynamically affected by chemotherapy, though the directionality of any interaction (whether exogenous cytochrome c would potentiate or interfere with chemotherapy) has not been established in clinical studies.

8.6 Nitration and Functional Disruption

Cytochrome c can be phosphorylated at four sites, indicating its regulation by cell signaling pathways. Conditions that alter kinase/phosphatase balance — including many pharmaceutical drugs and disease states — could theoretically alter cytochrome c's functional balance between respiration and apoptosis, though no dietary supplement is known to specifically modulate cytochrome c phosphorylation in a clinically characterized manner.

9. Summary of Evidence Strength

• Established biological role (electron transport, apoptosis): Evidence is robust and based on decades of molecular biology, structural studies, and genetic experiments across multiple species. These are foundational principles of cell biology, not claims under investigation.
• Serum cytochrome c as a clinical biomarker: Multiple observational clinical studies in patients with SIRS, cancer, liver disease, and acute kidney injury consistently support elevated circulating cytochrome c as a marker of cell death and organ injury. Evidence strength is moderate; studies are generally single-center, observational, and do not establish interventional benefit.
• Exogenous cytochrome c as an anticancer agent: Currently preclinical only. In vitro and animal model data are encouraging but no human trials exist. Translation faces significant unresolved challenges in stability, immunogenicity, and delivery.
• Cytochrome c as an oral supplement: No clinical or mechanistic evidence supports beneficial effects from oral ingestion of cytochrome c. The protein would be subject to gastrointestinal proteolysis, and no delivery system for oral use has been clinically validated. No recognized authority has evaluated it for this purpose.

References

• Cytochrome c: the Achilles' heel in apoptosis — PMC
• Cytochrome c phosphorylation: Control of mitochondrial electron transport chain flux and apoptosis — PMC
• New insight into the mechanism of mitochondrial cytochrome c function — PMC
• The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell — PMC
• Cytochrome c: Using Biological Insight toward Engineering an Optimized Anticancer Biodrug — PMC
• Cytochrome c and cancer cell metabolism: A new perspective — PMC
• Cytochrome C as a potential clinical marker for diagnosis and treatment of glioma — PMC
• Cytochrome c as a Potentially Clinical Useful Marker of Mitochondrial and Cellular Damage — PMC
• Circulating levels of Cytochrome c after Resuscitation from Cardiac Arrest: A Marker of Mitochondrial Injury and Predictor of Survival — PMC
• Cytochrome C is not released in the heart during sepsis-induced myocardial depression — PMC
• Molecular insights on cytochrome c and nucleotide regulation of apoptosome function and its implication in cancer — PMC
• Anticancer Nanoparticle Carriers of the Proapoptotic Protein Cytochrome c — PMC
• Chemical Modification of Cytochrome C for Acid-Responsive Intracellular Apoptotic Protein Delivery for Cancer Eradication — PMC
• Optimization and Characterization of Protein Nanoparticles for the Targeted and Smart Delivery of Cytochrome c to Non-Small Cell Lung Carcinoma — PMC
• A novel role of serum cytochrome c as a tumor marker in patients with operable cancer — PMC
• Extracellular cytochrome c as a biomarker for monitoring therapeutic efficacy and prognosis of non-small cell lung cancer patients — PubMed
• Serum cytochrome c level as a prognostic indicator in patients with systemic inflammatory response syndrome — PubMed
• Cytochrome c in cancer therapy and prognosis — Bioscience Reports
• The role of key residues in structure, function, and stability of cytochrome-c — PubMed
• Cytochrome c: Surfing Off of the Mitochondrial Membrane on the Tops of Complexes III and IV — PubMed
• Cytochrome c phosphorylation: Control of mitochondrial electron transport chain flux and apoptosis — PubMed
• Cytochrome C release from CNS mitochondria and potential for clinical intervention in apoptosis-mediated CNS diseases — PubMed
• Regulation of Cytochrome c Oxidase by Natural Compounds Resveratrol, (–)-Epicatechin, and Betaine — PMC
• Hallmarks of a new era in mitochondrial biochemistry — PMC
• Pathogenesis and treatment strategies of sepsis-induced myocardial injury: modern and traditional medical perspectives — PMC
• Cytochrome c — Wikipedia (citing primary literature)